SUTRO BIOPHARMA, INC. Short-Term Debt
SUTRO BIOPHARMA, INC. (STRO) had Short-Term Debt of $4.06 million as of 2023-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DebtCurrent · last filed 2025-03-13
- 2023-12-31: Debt, Current $4.06M.
- 2023-09-30: Debt, Current $7.14M.
- 2023-06-30: Debt, Current $10.20M.
- 2023-03-31: Debt, Current $13.24M.
| Period end | Debt, Current | Debt, Current as first filed |
|---|---|---|
| 2023-12-31 | $4.06M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $7.14M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $10.20M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $13.24M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $12.50M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $12.50M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $12.50M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $12.50M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $9.38M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $6.25M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $3.13M 10-Q · filed 2021-08-09 | |
| 2019-12-31 | $1.00M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $5.84M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $5.81M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $5.77M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $4.72M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $3.18M 10-Q · filed 2018-11-14 | |
| 2017-12-31 | $14.56M 10-K · filed 2019-04-01 | $14.63M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |